The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
BRCA1 and BRCA2 mutations and treatment strategies for breast cancer
Open accessAbstract
Breast cancer is a global burden with a woman's lifetime risk of developing breast cancer at 1 in 8.Although breast cancer is a disease that affects mostly women, the lifetime risk in men is about 1 in 1000.Most cases of breast cancer are associated with somatic mutations in breast cells that are acquired during a person's lifetime.In this scenario, the mutations are not inherited and they do not cluster in families.In hereditary breast cancer, the specific genetic factors involved will determine the inherited cancer risk.Inherited mutations in the BRCA1 or BRCA2 genes have been well-described, but mutations in ATM, CDH1, CHEK2, PALB2, PTEN, STK11, and TP53 also confer breast cancer risk.Understanding the functional significance of hereditary mutations has opened new paths for breast cancer prevention and is uncovering promising treatment strategies
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680 · cited 1×
“Although only 5 to 10% of breast cancer cases are inherited, recent estimates suggest that 55 to 65% of BRCA1 mutation carriers, and approximately 45% of BRCA2 mutation carriers will develop breast cancer by age 70 [19,20].”
BackgroundGenome-wide association study identifies novel breast cancer susceptibility loci
Easton, D. F., Pooley, K. A., Dunning, A. M., Pharoah, P. D. P., Thompson, D., Ballinger, D. G., Struewing, J. P., Morrison, J., Field, H., Luben, R., et al. (2007) · Nature · doi:10.1038/nature05887 · Cited by 2,319
A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage
Paull, T. T., Rogakou, E. P., Yamazaki, V., Kirchgessner, C. U., Gellert, M., & Bonner, W. M. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00610-2 · Cited by 2,098 · cited 1×
“In a study with 4398 breast cancer cases and 4316 controls, followed by a second Reference Protein Function of interacting protein [39] RAD51 Double strand break repair [40] RAD50 Double strand break repair [41] BASC complex Mismatch repair [42] H2AX Signaling of DNA damage [43] TP53 Tumor suppressor gene – Transcript…”
BackgroundRisks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850 · cited 1×
“Women with BRCA1 mutations have an increased risk of developing ovarian cancer, while men have a higher risk, to a lesser extent, of developing prostate cancer [16].”
BackgroundMeta-Analysis of BRCA1 and BRCA2 Penetrance
Chen, S., & Parmigiani, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.1066 · Cited by 1,802 · cited 1×
“Although only 5 to 10% of breast cancer cases are inherited, recent estimates suggest that 55 to 65% of BRCA1 mutation carriers, and approximately 45% of BRCA2 mutation carriers will develop breast cancer by age 70 [19,20].”
BackgroundAssociation of BRCA1 with Rad51 in Mitotic and Meiotic Cells
Scully, R., Chen, J., Plug, A., Xiao, Y., Weaver, D., Feunteun, J., Ashley, T., & Livingston, D. M. (1997) · Cell · doi:10.1016/s0092-8674(00)81847-4 · Cited by 1,459
Wang, Y., Cortez, D., Yazdi, P., Neff, N., Elledge, S. J., & Qin, J. (2000) · Genes & Development · doi:10.1101/gad.14.8.927 · Cited by 1,221
Rebbeck, T. R., Friebel, T., Lynch, H. T., Neuhausen, S. L., van ’t Veer, L., Garber, J. E., Evans, G. R., Narod, S. A., Isaacs, C., Matloff, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.188 · Cited by 1,171 · cited 1×
“For these women, a bilateral mastectomy is recommended, since studies have suggested that women who are BRCA1/2 mutation carriers and receive a bilateral mastectomy are less likely to die from breast cancer than women who were treated with unilateral mastectomy [82,83].”
BackgroundThe CHEK2-Breast Cancer Consortium (2002) · Nature Genetics · doi:10.1038/ng879 · Cited by 1,104
Homologous Recombination and Human Health: The Roles of BRCA1, BRCA2, and Associated Proteins
Prakash, R., Zhang, Y., Feng, W., & Jasin, M. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016600 · Cited by 869 · cited 1×
“Simultaneously, BRCA1 controls the signaling involved in homologous recombination and it ensures that the double strand break is not resected before RAD51 protein formation [36].”
BackgroundBRCA1 and BRCA2 and the genetics of breast and ovarian cancer
Welcsh, P. L. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.705 · Cited by 648 · cited 1×
“Patients with BRCA1 or BRCA2 mutations frequently harbor TP53 mutations, and it is thought that several oncogenes undergo mutation as a result of BRCA insufficiency [34].”
BackgroundAssociation of BRCA1 with the hRad50-hMre11-p95 Complex and the DNA Damage Response
Zhong, Q., Chen, C.-F., Li, S., Chen, Y., Wang, C.-C., Xiao, J., Chen, P.-L., Sharp, Z. D., & Lee, W.-H. (1999) · Science · doi:10.1126/science.285.5428.747 · Cited by 626
Brekelmans, C. T. M., Tilanus-Linthorst, M. M. A., Seynaeve, C., vd Ouweland, A., Menke-Pluymers, M. B. E., Bartels, C. C. M., Kriege, M., van Geel, A. N., Burger, C. W., Eggermont, A. M. M., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.12.009 · Cited by 233 · cited 2×
“A multivariate study, including 223 breast cancer patients carrying BRCA mutations and 446 controls with sporadic breast cancer matched for age and year of diagnosis, showed no difference in terms of specific breast cancer survival between BRCA1 mutation carriers and sporadic cases, or between overall survival for BRC…”
BackgroundMethod
Cited by
Győrffy, B. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.07.014 · Cited by 1,648
Epidemiological characteristics of and risk factors for breast cancer in the world
Momenimovahed, Z., & Salehiniya, H. (2019) · Breast Cancer: Targets and Therapy · doi:10.2147/bctt.s176070 · Cited by 1,050
PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects
Miricescu, D., Totan, A., Stanescu-Spinu, I.-I., Badoiu, S. C., Stefani, C., & Greabu, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010173 · Cited by 845
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Rose, M., Burgess, J. T., O’Byrne, K., Richard, D. J., & Bolderson, E. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.564601 · Cited by 719
An Overview of PARP Inhibitors for the Treatment of Breast Cancer
Cortesi, L., Rugo, H. S., & Jackisch, C. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00796-4 · Cited by 393
Metadata
- Authors
- Godet, I., & M. Gilkes, D.
- Venue
- Integrative Cancer Science and Therapeutics
- Publisher
- Open Access Text Pvt, Ltd.
- Published
- 2017
- Volume
- 4
- Issue
- 1
- ISSN
- 2056-4546 (ISSN-L)
- OpenAlex
- W2604876648
- Cited by
- 250
- References
- 14
- FWCI
- 10.15
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.